REG-Arix Bioscience PLC Transaction in own shares

Arix BioscienceAnnouncement

13/10/2021 17:35

============

   Arix Bioscience PLC (ARIX)
   Transaction in own shares

   13-Oct-2021 / 17:30 GMT/BST
   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

                              Arix Bioscience plc

    

                           Transaction in own shares

    

   LONDON, 13 October  2021: Arix  Bioscience plc ("Arix"  or "the  Company")
   (LSE:ARIX), a global venture capital  company focused on investing in  and
   building breakthrough biotech companies, today announces that it purchased
   the following number  of its ordinary  shares of 0.001  pence each on  the
   London Stock Exchange from  Jefferies International Limited  as part of  a
   buyback programme announced on 22 March 2021.

    

   Date of purchase                     13 October 2021
   Aggregate number of shares purchased 61,000
   Highest price paid per share         144.00p
   Lowest price paid per share          144.00p
   Average price paid per share         144.00p

    

   Arix intends to retain the purchased shares in treasury.

   Following settlement of  the above  purchase, Arix  will have  129,302,800
   ordinary shares of 0.001 pence each in issue (excluding 6,306,853 ordinary
   shares of 0.001p each held in treasury). This number represents the  total
   voting rights in Arix and may  be used by shareholders as the  denominator
   for the calculations by which they  can determine if they are required  to
   notify their interest in,  or a change to  their interest in, the  Company
   under the Financial Conduct Authority's Disclosure and Transparency Rules.

   In accordance with  Article 5(1)(b)  of Regulation (EU)  No. 596/2014  (as
   incorporated into UK domestic law  by the European Union (Withdrawal)  Act
   2018), the schedule below contains detailed information of the  individual
   trades made  by Jefferies  International Limited  as part  of the  buyback
   programme.

                                      ENDS 

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

    1 ir@arixbioscience.com

    

   Optimum Strategic Communications

   Mary Clark, Manel Mateus

   +44 (0)20 8078 4357

    2 optimum.arix@optimumcomms.com

    

   About Arix Bioscience plc

   Arix Bioscience  plc  is  a  global venture  capital  company  focused  on
   investing  in   and  building   breakthrough  biotech   companies   around
   cutting-edge advances in life sciences.

   We collaborate  with exceptional  entrepreneurs and  provide the  capital,
   expertise  and  global  networks  to  help  accelerate  their  ideas  into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting  growth phase of  our industry to  a broader range  of
   investors.  3 www.arixbioscience.com

    

    

    

   Transaction Transaction Volume Price  Platform    Transaction Reference
      Date        Time            (GBp)                     Number
                                          London
   13/10/2021   09:57:17   61,000 144.00  Stock        00265813213TRLO1
                                         Exchange

    

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  POS
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares
   Sequence No.:   124298
   EQS News ID:    1240612


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    4 fncls.ssp?fn=show_t_gif&application_id=1240612&application_name=news&site_id=refinitiv2

References

   Visible links
   1. mailto:ir@arixbioscience.com
   2. mailto:optimum.arix@optimumcomms.com
   3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=0e82cce39f5bc66fe0ead5d02956d352&application_id=1240612&site_id=refinitiv2&application_name=news


============